SAN CARLOS, Calif.--September 23, 2026--Glycomine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GLM101 for the treatment of phosphomannomutase 2 congenital...
Arthur Klausner will participate on a panel at the Biotechnology Entrepreneurship Boot Camp program that is associated with the the BIO International Convention in San Diego, CA
News | 06. 17. 2008
